Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance-MedSci.cn

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance

Nash, P; Mease, PJ; Fleishaker, D; Wu, J; Coates, LC; Behrens, F; Gladman, DD; Kivitz, AJ; Wei, JC; Shirinsky, I; Menon, S; Romero, AB; Fallon, L; Hsu, MA; Wang, CS; Kanik, KS

Fleishaker, D (corresponding author), Pfizer Inc, Groton, CT 06340 USA.

LANCET RHEUMATOLOGY, 2021; 3 (1): E28

Abstract

Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. This ......

Full Text Link